A study testing whether a study medicine from Abbott Diabetes Care, investigational drug, can lower blood sugar and help with weight.

Who can join: Adults 18+, have diabetes.
What you take: investigational drug, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts: The full study runs about 2.3 years; your own time in it is usually shorter.
What you get: The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

Phase Not ApplicableSponsor Abbott Diabetes CareDrug investigational drugClass OtherSites 2 USEnrollment target 800

What this study is for

Primary condition: Diabetes Mellitus.

Full scientific study title: Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring.

Who can join

Age18 and upSexAny

Adults 18+, have diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Subject must be at least 18 years of age.
Subject must be able to read and understand English.
Subject must have a type 2 diabetes diagnosis.
In the investigator's opinion, subject must meet the criteria for beginning use of GLP-1 or GIP/GLP-1 medications for management of their diabetes.
Subject is beginning use of GLP-1 / GIP/GLP-1 medication for management of their diabetes.

Key exclusion criteria

Subject is a member of the Study Staff.
Subject has a diagnosis of type 1 or gestational diabetes.
Subject is currently using or has previously used GLP-1 or GIP/GLP-1 drugs for any reason.
Subject is currently using a Continuous Glucose Monitor (CGM) as their standard of care device to manage their diabetes.
Subject has known allergy to medical grade adhesive, isopropyl alcohol and/or ethyl alcohol used to disinfect skin.

Where this study is enrolling

This trial has 2 sites across 1 state. Contact a site coordinator directly to start screening.

Florida2 sites

East Coast Institute for Research, LLC
Jacksonville, Florida
Rebecca Goldfaden, Pharm D904-854-1354rg@eastcoastresearch.net
Excellence Medical and Research
Miami Gardens, Florida
Alexander Martinez, OD786-320-5229amartinez@emrclinic.com

Follow this trial

We email you if NCT06668935 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: 2024-10-24. Expected completion: 2027-01. Last updated on ClinicalTrials.gov: 2025-01-15.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.